Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

As the RCC field braces for another paradigm change, early studies combining tyrosine kinase inhibitors with PD-1/L1 inhibitors suggest the highest response rates are found with Inlyta (axitinib) as a partner.